Atropine, a competitive muscarinic receptor antagonist, is most commonly used in the treatment of organophosphate poisoning; to reverse bradycardia including that of amitraz poisoning; to prevent secretions prior to induction of general anesthesia; in addition to to blocking muscarinic side effects of anticholinesterase drugs such as neostigmine, physistigmine.
Atropine acts immediately (peak effects observed in 3 min justifying 5 min interval of administration) and is relatively safe when used at therapeutic doses. Fatalities from atropine toxicity are rare but sometimes occur in children at doses of 10mg or less.
Atropine toxicity effects generally correlates with dosage. However, toxicity may result . . .
Please Subscribe to continue reading
